Stock listing

Frankfurt:5VA Vaxcyte, Inc. Aktie

German listing (Frankfurt) of Vaxcyte, Inc. · home listing NASDAQ:PCVX

Follow Vaxcyte, Inc. into a list and get an email when it puts out news.

Share price · FWB:5VA

€53.00 EUR +0.50 (+1.0%)

Close on Oct 23, 2026

Day range
€53.00 – €53.00 EUROct 23, 2026
Market cap
€8.34B EURAt the close on Oct 23, 2026 · price × 157.4M shares outstanding
Vaxcyte, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PCVX · Home$60.43 USD-2.42 (-3.9%)2,062,400$62.35$62.77$60.27$62.85Close on Oct 23, 2026
Frankfurt:5VA€53.00 EUR+0.50 (+1.0%)—€53.00€53.00€53.00€52.50Close on Oct 23, 2026
Ticker
Frankfurt:5VA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 4:30 PM ET

    Watch Transcript

  • Vaxcyte (NASDAQ:PCVX) Q4 2024 Earnings Call

    Tue, Feb 25, 2025 · 1:30 PM ET

    Watch Transcript

  • Vaxcyte (NASDAQ:PCVX) Q4 2023 Earnings Call

    Tue, Feb 27, 2024 · 4:30 PM ET

    Watch Transcript

Latest news

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Oct 9, 2026

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Oct 6, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Oct 5, 2026

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Sep 3, 2026

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 5, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

Jul 8, 2026

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Jun 2, 2026

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Mar 23, 2026

All Vaxcyte, Inc. news

Financings

  • Public offering of common stock and pre-funded warrants

    Oct 9, 2026

    Closed: US$500M raised · US$64 a share · Jefferies +7

    Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Goldman Sachs & Co. LLC (co-lead), Guggenheim Securities (co-lead), Mizuho, BTIG

    Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes

    Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026

  • 1.50% convertible senior notes due 2032

    Oct 9, 2026

    Closed: US$575M raised · Jefferies +8

    Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, Mizuho, Needham & Company, J. Wood Capital Advisors

    Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes

    Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026

Read by 6ix AI from the company's releases

Decks

Vaxcyte, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 127 in all · newest Oct 9, 2026 · oldest 2020
Calls
5 calls with a replay · 5 with a transcript · latest Feb 24, 2026
Decks
9 decks · latest Oct 5, 2026

Where Vaxcyte, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PCVX · Home listingNASDAQUnited StatesUSD
gettex:5VAgettexGermanyEUR
LS Exchange:A2P6R6LS ExchangeGermanyEUR
Lang & Schwarz:A2P6R6Lang & SchwarzGermanyEUR
Milan:1PCVXMilanItalyEUR
BOATS:PCVXBOATSUnited StatesUSD
Frankfurt:5VA · This pageFrankfurtGermanyEUR
BX Swiss:PCVXBX SwissSwitzerlandCHF
Dusseldorf:5VADusseldorfGermanyEUR
Hamburg:5VAHamburgGermanyEUR
Munich:5VAMunichGermanyEUR
Stuttgart:5VAStuttgartGermanyEUR
Tradegate:5VATradegateGermanyEUR
Hanover:5VAHanoverGermanyEUR
Xetra:5VAXetraGermanyEUR

Log in to ask 6ix AI your own questions about Vaxcyte, Inc.